Corcept Therapeutics (NASDAQ: CORT) is a pharmaceutical company that develops and markets drugs for serious metabolic, oncologic, and psychiatric disorders. Revenue comes entirely from sales of its cortisol modulation drug Korlym (mifepristone 300 mg), prescribed for hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome. The filing excerpts provided do not contain sufficient detail to characterize market position, competitive set, segment revenue breakdown, unit economics, capital structure, founding history, or leadership with the specificity required for grounded claims.

Revenue model

Product sales of Korlym (mifepristone 300 mg), a prescription pharmaceutical for Cushing's syndrome. Revenue is transactional, generated per prescription filled.

Products and services

Korlym (mifepristone 300 mg): cortisol modulator approved for hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome.

Customers and end markets

Patients with endogenous Cushing's syndrome; prescribing physicians in endocrinology and related specialties.

Value-chain role

Drug developer and commercial-stage pharmaceutical manufacturer/marketer.

Source: SEC 10-K, filed 2026-02-24

Industry: Pharmaceutical Preparations Peers: Arvinas Inc Pacira Biosciences Inc Elanco Animal Health Inc Harmony Biosciences Holdings Inc Intra-Cellular Therapies, Inc. Johnson & Johnson Organon & Co Prestige Consumer Healthcare Inc Viatris Inc